Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Shares Issued (2017 - 2025)

Voyager Therapeutics' Shares Issued history spans 9 years, with the latest figure at $21000.0 for Q4 2025.

  • For Q4 2025, Shares Issued rose 100.02% year-over-year to $21000.0; the TTM value through Dec 2025 reached $267000.0, down 31.19%, while the annual FY2025 figure was $267000.0, 31.19% down from the prior year.
  • Shares Issued for Q4 2025 was $21000.0 at Voyager Therapeutics, up from -$188000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $93.4 million in Q2 2024 and bottomed at -$93.1 million in Q4 2024.
  • The 5-year median for Shares Issued is $82000.0 (2025), against an average of $218823.5.
  • The largest YoY upside for Shares Issued was 69597.76% in 2024 against a maximum downside of 404817.39% in 2024.
  • A 5-year view of Shares Issued shows it stood at $556000.0 in 2021, then tumbled by 95.14% to $27000.0 in 2022, then fell by 14.81% to $23000.0 in 2023, then tumbled by 404817.39% to -$93.1 million in 2024, then skyrocketed by 100.02% to $21000.0 in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Shares Issued are $21000.0 (Q4 2025), -$188000.0 (Q3 2025), and $352000.0 (Q2 2025).